KR100523506B1 - Peptide and O-glycan inhibitors of selectin mediated inflammation - Google Patents

Peptide and O-glycan inhibitors of selectin mediated inflammation

Info

Publication number
KR100523506B1
KR100523506B1 KR10-2004-7004565A KR20047004565A KR100523506B1 KR 100523506 B1 KR100523506 B1 KR 100523506B1 KR 20047004565 A KR20047004565 A KR 20047004565A KR 100523506 B1 KR100523506 B1 KR 100523506B1
Authority
KR
South Korea
Prior art keywords
glycans
glycan
peptide
beta
disialylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR10-2004-7004565A
Other languages
English (en)
Korean (ko)
Other versions
KR20040039440A (ko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of KR20040039440A publication Critical patent/KR20040039440A/ko
Application granted granted Critical
Publication of KR100523506B1 publication Critical patent/KR100523506B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR10-2004-7004565A 1995-08-03 1996-08-02 Peptide and O-glycan inhibitors of selectin mediated inflammation Expired - Fee Related KR100523506B1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US51092095A 1995-08-03 1995-08-03
US1779496P 1996-05-15 1996-05-15
US60/017,794 1996-05-15
US64980296A 1996-05-17 1996-05-17
US08/510,920 1996-05-17
US08/649,802 1996-05-17
PCT/US1996/012820 WO1997006176A2 (en) 1995-08-03 1996-08-02 Peptide and o-glycan inhibitors of selectin mediated inflammation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR19980700761A Division KR100463567B1 (ko) 1995-08-03 1996-08-02 셀렉틴매개염증의펩티드및0-글리칸억제제

Publications (2)

Publication Number Publication Date
KR20040039440A KR20040039440A (ko) 2004-05-10
KR100523506B1 true KR100523506B1 (en) 2005-10-24

Family

ID=27360885

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7004565A Expired - Fee Related KR100523506B1 (en) 1995-08-03 1996-08-02 Peptide and O-glycan inhibitors of selectin mediated inflammation

Country Status (11)

Country Link
EP (1) EP0850243B1 (https=)
JP (1) JPH11510543A (https=)
KR (1) KR100523506B1 (https=)
AT (1) ATE251636T1 (https=)
AU (1) AU723262B2 (https=)
CA (1) CA2228512A1 (https=)
DE (1) DE69630307T2 (https=)
DK (1) DK0850243T3 (https=)
ES (1) ES2208759T3 (https=)
MX (1) MXPA98000968A (https=)
WO (1) WO1997006176A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
JP2002518354A (ja) 1998-06-16 2002-06-25 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ オクラホマ 糖硫酸ペプチド、その合成方法および使用方法
US20030143662A1 (en) 1998-06-16 2003-07-31 Cummings Richard D. Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof
US7223845B2 (en) 1998-06-16 2007-05-29 The Board Of Regents Of The University Of Oklahoma Synthetic glycosulfopeptides and methods of synthesis thereof
CA2347119A1 (en) * 1998-10-30 2000-05-11 Genetics Institute, Inc. Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists
CA2347940A1 (en) * 1998-11-21 2000-06-02 The Regents Of The University Of California Use of core 2 glcnac transferase inhibitors in treating inflammation
US6492152B1 (en) 1999-06-15 2002-12-10 The Board Of Regents Of The University Of Oklahoma Core 1 β3-galactosyl transferases and methods of use thereof
US7256171B1 (en) 1999-11-20 2007-08-14 The Regents Of The University Of California Use of core 2 G1cNAc transferase inhibitors in treating inflammation
EP1325123A4 (en) * 2000-09-12 2004-07-21 Inst Genetics Llc STENOSE- OR RESEARCH INHIBITION BY P-SELECTIN ANTAGONISTS
EP1406930A4 (en) * 2000-12-29 2007-01-10 Savient Pharmaceuticals Inc "ISOLATED MOLECULES WITH SULFATED GROUPING CONTAINING EPITOPES, ANTIBODIES AGAINST SUCH EPITOPES AND USES THEREOF"
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
WO2004012817A2 (en) * 2002-07-31 2004-02-12 Kylix B.V. Use of genes identified to be involved in tumor development for the development of anti-cancer drugs
JP4599027B2 (ja) * 2002-10-30 2010-12-15 東洋水産株式会社 Ｌ−セレクチン結合阻害剤
FI20021989A0 (fi) * 2002-11-06 2002-11-06 Halina Miller-Podraza Korkean affiniteetin Helicobacter pylori-reseptorit ja niiden käyttö
GB0329667D0 (en) 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
GB0513881D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
UY28886A1 (es) 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
ES2655833T3 (es) 2004-05-11 2018-02-21 AbGenomics Coöperatief U.A. Epítopos que inducen la muerte de células T
GB0513888D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
GB0513883D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
US20070298034A9 (en) * 2005-12-09 2007-12-27 Angela Widom Sulfotyrosine specific antibodies and uses therefor
JP5331293B2 (ja) * 2006-04-28 2013-10-30 公益財団法人野口研究所 多様性を表現するオリゴ糖またはその誘導体
PL2664596T3 (pl) * 2008-09-02 2019-05-31 Construction Research & Tech Gmbh Sposób wytwarzania kompozycji środka przyspieszającego utwardzanie zawierającej plastyfikator
BR112012009500A2 (pt) * 2009-10-21 2016-11-29 Eth Zuerich utilidade médica de proteínas de ligação de glicano e glicanos
EP2718325A4 (en) 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
KR20250159733A (ko) 2017-01-11 2025-11-11 브리스톨-마이어스 스큅 컴퍼니 Psgl-1 길항제 및 그의 용도
PE20250933A1 (es) 2017-03-14 2025-04-02 Five Prime Therapeutics Inc Anticuerpos de union a vista a ph acido
BR112020019083A2 (pt) 2018-03-21 2020-12-29 Five Prime Therapeutics, Inc. Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
PE20210687A1 (es) 2018-07-11 2021-04-08 Bristol Myers Squibb Co Anticuerpos de union a vista a ph acido

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU681369B2 (en) * 1992-11-16 1997-08-28 Board Of Regents Of The University Of Oklahoma, The Glycoprotein ligand for P-selectin and methods of use thereof
WO1995030001A2 (en) * 1994-04-28 1995-11-09 Genetics Institute, Inc. Novel p-selectin ligand protein

Also Published As

Publication number Publication date
WO1997006176A2 (en) 1997-02-20
ES2208759T3 (es) 2004-06-16
CA2228512A1 (en) 1997-02-20
DE69630307T2 (de) 2004-07-15
AU6766996A (en) 1997-03-05
DK0850243T3 (da) 2004-02-02
KR20040039440A (ko) 2004-05-10
EP0850243A2 (en) 1998-07-01
JPH11510543A (ja) 1999-09-14
WO1997006176A3 (en) 1997-07-24
ATE251636T1 (de) 2003-10-15
EP0850243B1 (en) 2003-10-08
DE69630307D1 (de) 2003-11-13
AU723262B2 (en) 2000-08-24
MXPA98000968A (es) 2002-07-15

Similar Documents

Publication Publication Date Title
KR100523506B1 (en) Peptide and O-glycan inhibitors of selectin mediated inflammation
AU6210698A (en) Carbohydrate mixture
Capek et al. An acetylated galactoglucomannan from Picea abies L. Karst
Linsley et al. Applications of electrospray mass spectrometry to erythropoietin N-and O-linked glycans
PL346642A1 (en) Carbohydrates mixture
CA2110386A1 (en) Method for the Enzymatic Synthesis of Alpha-Sialylated Oligosaccharide Glycosides
MY119768A (en) Fibre blend for enteral composition.
RU2008129102A (ru) Применение растворимых пищевых волокон против мышечной атрофии
Inoue et al. Characterization of a new type of glycoprotein saccharides containing polysialosyl sequence
Wieruszeski et al. Structure of two new oligosaccharides isolated from human milk: sialylated lacto-N-fucopentaoses I and II
Nergard et al. Structure-immunomodulating activity relationships of a pectic arabinogalactan from Vernonia kotschyana Sch. Bip. ex Walp.
Klein et al. Isolation and structural characterization of novel sialylated oligosaccharide‐alditols from respiratory‐mucus glycoproteins of a patient suffering from bronchiectasis
AU571349B2 (en) Membrane polysaccharides
Tsuji et al. The carbohydrate moiety of Band-3 glycoprotein of human erythrocyte membranes
Degroote et al. Sulfated oligosaccharides isolated from the respiratory mucins of a secretor patient suffering from chronic bronchitis
Lloyd et al. Immunochemical studies on blood groups. XXXVII. The structures of difucosyl and other oligosaccharides produced by alkaline degradation of blood group A, B, and H substances. Optical rotatory dispersion and circular dichroism spectra of these oligosaccharides
Aeed et al. Characterization of the O-linked oligosaccharide structures on P-selectin glycoprotein ligand-1 (PSGL-1)
Chalabi et al. The expression of free oligosaccharides in human seminal plasma
FINNE et al. Structural features of the carbohydrate units of plasma glycoproteins
Joseleau et al. Structure of the capsular polysaccharide of Klebsiella K-type 63
Margolis et al. Structural studies on glycoprotein oligosaccharides of chromaffin granule membranes and dopamine β-hydroxylase
Kitajima et al. Analytical methods for identifying and quantitating deamidated sialic acid (2-keto-3-deoxy-d-glycero-d-galactonononic acid) and α2→ 8-linked poly (oligo) nonulosonate residues in glycoconjugates
Chandrasekaran et al. Structures of the oligosaccharide chains in swine trachea mucin glycoproteins.
Hellerqvist et al. Structural studies of the O-specific side-chains of the cell-wall lipopolysaccharide from Salmonella senftenberg
Tyler et al. Specific capsular polysaccharide of type VII Pneumococcus

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 20081018

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20081018

St.27 status event code: N-4-6-H10-H13-oth-PC1903

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000